Innovita Biological Technology Co., Ltd.

SHSE:688253 Stock Report

Market Cap: CN¥4.4b

Innovita Biological Technology Past Earnings Performance

Past criteria checks 1/6

Innovita Biological Technology's earnings have been declining at an average annual rate of -3.8%, while the Medical Equipment industry saw earnings declining at 3.5% annually. Revenues have been growing at an average rate of 23.6% per year. Innovita Biological Technology's return on equity is 9.5%, and it has net margins of 35.9%.

Key information

-3.80%

Earnings growth rate

-17.45%

EPS growth rate

Medical Equipment Industry Growth15.97%
Revenue growth rate23.62%
Return on equity9.51%
Net Margin35.86%
Last Earnings Update31 Mar 2025

Recent past performance updates

We Think Innovita Biological Technology's (SHSE:688253) Robust Earnings Are Conservative

Nov 01
We Think Innovita Biological Technology's (SHSE:688253) Robust Earnings Are Conservative

Recent updates

Is Innovita Biological Technology Co., Ltd. (SHSE:688253) Potentially Undervalued?

Mar 20
Is Innovita Biological Technology Co., Ltd. (SHSE:688253) Potentially Undervalued?

Innovita Biological Technology Co., Ltd.'s (SHSE:688253) Subdued P/E Might Signal An Opportunity

Jan 27
Innovita Biological Technology Co., Ltd.'s (SHSE:688253) Subdued P/E Might Signal An Opportunity

We Think Innovita Biological Technology's (SHSE:688253) Robust Earnings Are Conservative

Nov 01
We Think Innovita Biological Technology's (SHSE:688253) Robust Earnings Are Conservative

Investors Could Be Concerned With Innovita Biological Technology's (SHSE:688253) Returns On Capital

Sep 28
Investors Could Be Concerned With Innovita Biological Technology's (SHSE:688253) Returns On Capital

Statutory Profit Doesn't Reflect How Good Innovita Biological Technology's (SHSE:688253) Earnings Are

Apr 22
Statutory Profit Doesn't Reflect How Good Innovita Biological Technology's (SHSE:688253) Earnings Are

There's Reason For Concern Over Innovita Biological Technology Co., Ltd.'s (SHSE:688253) Massive 25% Price Jump

Mar 20
There's Reason For Concern Over Innovita Biological Technology Co., Ltd.'s (SHSE:688253) Massive 25% Price Jump

Revenue & Expenses Breakdown

How Innovita Biological Technology makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

SHSE:688253 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Mar 25547196135110
31 Dec 2462124715497
30 Sep 2472033213880
30 Jun 2467630313475
31 Mar 2462526613465
31 Dec 2347817410453
30 Sep 2341511010058
30 Jun 2342012010261
31 Mar 2351217810171
31 Dec 224471519772
30 Sep 223731438657
30 Jun 223601337949
31 Mar 22267788136
31 Dec 213271208431
31 Dec 201,03757115359
31 Dec 19138216621
31 Dec 1879173411

Quality Earnings: 688253 has high quality earnings.

Growing Profit Margin: 688253's current net profit margins (35.9%) are lower than last year (42.6%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 688253's earnings have declined by 3.8% per year over the past 5 years.

Accelerating Growth: 688253's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: 688253 had negative earnings growth (-26.4%) over the past year, making it difficult to compare to the Medical Equipment industry average (-3.5%).

Return on Equity

High ROE: 688253's Return on Equity (9.5%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/18 22:01
End of Day Share Price 2025/05/16 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Innovita Biological Technology Co., Ltd. is covered by 2 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Wen DaiHuatai Research
Ban WangMinsheng Securities Co.